Early-life vancomycin and meropenem treatment exert distinct effects on microbiota-gut-brain axis signalling in zebrafish larvae

The human body is not a solitary island; it is a bustling ecosystem. Trillions of microscopic organisms, mostly bacteria, live within our digestive tracts, forming a community that does far more than just help us digest food. These microbes communicate constantly with our brains, sending chemical signals that influence our mood, our stress levels, and even how we behave. Scientists call this the microbiota-gut-brain axis. While we know that this connection exists, the precise language these two systems speak remains a mystery. We know that when the balance of gut bacteria is disturbed, the brain often reacts, but we do not fully understand how different types of disturbances lead to different outcomes. Does wiping out a specific group of bacteria cause a different kind of trouble than wiping out a broader range? To answer this, researchers need a way to watch these interactions happen in real time, in a living system that is simple enough to study but complex enough to matter.

To explore these questions, a team of scientists turned to the zebrafish, a small, transparent freshwater fish that has become a standard model for studying development. In their earliest days, these fish larvae are so clear that researchers can see their internal organs and even the activity of their brains without cutting them open. More importantly, their immune systems are not fully developed at this stage, allowing scientists to study the raw relationship between the host and its microbes without the interference of a complex immune response. The researchers focused on a critical window of time: the first five days of the fish's life. They wanted to see what happens when the delicate community of gut bacteria is disrupted by antibiotics, the powerful medicines used to kill bacteria in humans. Specifically, they tested two very different drugs: vancomycin, which targets a specific group of bacteria, and meropenem, a broad-spectrum drug that attacks a wide variety of bacterial types. By comparing the effects of these drugs, both alone and in combination, the team hoped to uncover how the specific nature of a microbial disturbance shapes the developing brain and behavior.

The researchers began by exposing the tiny fish larvae to these antibiotics in their water. They then watched how the bacteria inside the fish changed. As expected, the drugs altered the microbial community, but the way they did so was distinct. The broad-spectrum drug, meropenem, caused a massive reshuffling of the bacterial population, wiping out the dominant types and allowing new, previously rare groups to take their place. The more targeted drug, vancomycin, caused much smaller changes, affecting only a few specific types of bacteria while leaving the rest of the community largely intact. This confirmed that the two drugs created two very different microbial environments, even though both were classified as antibiotic treatments.

Next, the team observed the behavior of the fish. They placed the larvae in a tank that was half light and half dark, a setup designed to measure anxiety. Healthy fish usually feel safe in the dark and will swim into the center of the tank when the lights go out. However, the fish that had been treated with antibiotics behaved differently. All three groups of treated fish—the ones with vancomycin, the ones with meropenem, and the ones with both—showed signs of increased anxiety. They were less willing to swim into the center of the tank during the dark phase compared to the untreated fish. This suggested that simply having a disrupted gut, regardless of how it was disrupted, made the fish more anxious. Yet, there was a nuance: the fish treated with the combination of both drugs showed a slightly different pattern of movement at the start of the test, suggesting that the specific mix of antibiotics might influence how the fish reacted to new environments.

The scientists then looked inside the fish to see what was happening chemically. They measured the levels of serotonin, a key chemical in the brain that regulates mood and anxiety. They found that the ability of the fish to make serotonin was reduced in all the treated groups, as the genes responsible for producing it were turned down. However, the actual amount of serotonin in the brain did not change dramatically, except in one group. The fish treated with meropenem alone had higher levels of serotonin than the others, a finding that did not match the pattern seen with the other drugs. This indicated that while the drugs all suppressed the machinery for making serotonin, the meropenem group had a unique chemical environment that allowed levels to rise despite the suppression.

Beyond the brain, the researchers analyzed the chemical soup of the fish's entire body. They discovered that the antibiotics had caused widespread changes in metabolism, the process by which the body turns food into energy and building blocks. Some changes were common to all groups, such as a drop in lysine, an essential nutrient that the fish cannot make on its own and must get from its diet or its microbes. This drop suggested that the antibiotics had cut off a vital supply line. Other changes were specific to the type of drug used. The fish treated with meropenem showed a surge in several neurotransmitters in their bodies, including glutamate and GABA, which are involved in sending signals between nerve cells. In contrast, the fish treated with vancomycin showed a specific drop in a group of molecules called polyamines, which are crucial for cell growth and development. The combination of both drugs created yet another unique chemical signature, lowering levels of a key energy molecule called NAD+ in the brain, which could affect how the brain cells function.

The study concludes that the impact of antibiotics on the developing brain is not just a matter of how much the gut bacteria are disturbed, but rather how they are disturbed. A broad, sweeping change in the microbial community leads to different chemical and behavioral outcomes than a narrow, targeted change. The researchers found that the specific mix of bacteria that remains after treatment dictates the chemical signals sent to the brain, influencing everything from anxiety levels to the availability of essential nutrients. These findings highlight that the gut microbiome is a dynamic partner in brain development, and that disrupting it with different tools can lead to distinct consequences. While the study was conducted in fish, it offers a clear window into the complex dialogue between our internal microbes and our minds, suggesting that the specific nature of a medical intervention could have long-lasting effects on how the brain develops and functions.